Insilico Medicine announces artificial intelligent (AI) system powered by Intel architecture to help researchers and clinicians engage in COVID-19 research
Credit: Insilico
8th of September, 2020, (9AM PST) — Today Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, announced the launch of a new system for COVID-19 basic and clinical research. COVIDomic is a foundational technology which enables scientists to use anonymized patient data to integrate with a variety of existing data sets. Bioinformatics and Artificial Intelligence (AI) tools can then be applied in many ways, starting with better stratifying COVID-19 patients, understanding the disease trajectory and identifying relevant disease pathways and targets. COVIDomic is built using massive multi-omics data sets, sophisticated dimensionality reduction algorithms and deep learning systems. This amount of computing will rely on Intel Xeon processors.
The development team is inviting scientists globally to contribute to the development of the system and engage in active research collaborations.
COVIDomic is a cloud-based platform that uses AI approaches to identify risk factors associated with severe disease progression. A researcher can upload wide combinations of patient data, including viral and human genomes, rich metadata (describing patient’s lifestyle, co-morbid disorders and biological age), results of blood tests and even transcriptomic sequencing of lung fluid or nasal swabs (to identify changes in microbial communities). As a result, the platform identifies the minimum number of relevant features that could be used to define severe disease progression for a given population.
“COVIDomic is an open access tool to stratify risk and severity from multimodal data sets, including multi-omics data. Insilico Medicine’s AI-driven generative biology approach is a unique offering in the marketplace. We are part of many COVID-19 consortiums and collaborations but COVIDomic is a system that will help scientists and researchers alike to predict the severity of the disease,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “By predicting outcomes, clinicians can establish protocols and treatments we hope will reduce the severity and mortality of infection.”
“Analyzing massive amounts of data – quickly – across geographies and data sets is essential for gaining insights into how the novel coronavirus affects people across the world,” noted Rick Echevarria, Intel Vice President, Sales, Marketing, and Communications Group. “Intel computing power enables AI that can help researchers in the fight against COVID-19. We hope that by sharing our expertise, resources and technology we can help accelerate research across diverse geographies and with companies such as Insilico Medicine.”
###
About Insilico Medicine:
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes. Since its inception, Insilico Medicine, raised over $52 million from expert biopharmaceutical and technology investors, published over 100 peer-reviewed scientific papers, applied for over 25 patents, generated millions in revenue from partnerships with pharmaceutical companies and received multiple industry awards. Website: https:/
Media Contact
Polina Firsanova
[email protected]
